Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
Anne Aupérin, Cecile Le Péchoux, Estelle Rolland...
https://pubmed.ncbi.nlm.nih.gov/20351327/Actively Recruiting
Led by University of Aarhus · Updated on 2026-03-04
500
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating high-dose reirradiation reRT for patients with recurrent or new thoracic cancers, including lung cancer and solitary lung metastases. This multicentre prospective cohort study aims to collect detailed data on radiotherapy-related toxicity, loco-regional control, and overall survival to improve the safety and effectiveness of reRT. The study also seeks to establish guidelines for dose accumulation and organ protection to standardize treatment strategies. All patients eligible for reirradiation will receive radiotherapy following established dose limits, with no additional interventions as this is an observational registration study. The study involves collecting previous treatment data, including digital dose plans, and monitoring patients through regular thoracic CT scans and clinical assessments. Follow-up is conducted every three months for two years and then every six months up to five years, capturing toxicity levels and patient-reported outcomes. Participants will undergo thorough baseline assessments of prior treatments, comorbidities, and toxicity. Researchers will monitor adverse events using standardized criteria and evaluate quality of life and decision regret through validated questionnaires at baseline, three months, and annually. Data on survival, disease progression, and treatment compliance will also be collected, supporting individualized treatment decisions and enhancing understanding of reirradiation risks and benefits over a long-term period extending up to five years.
CONDITIONS
Curatively Intended Thoracic Reirradiation
S
Stine O Fredslund, MD, PhD
L
Lone Hofmann, Physicist
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Aarhus
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who undergo routine thoracic reirradiation are observed. Data on previous treatments, toxicity, and patient-reported outcomes are collected to understand the effects of high-dose reirradiation.
Clinical follow-up visits every 3 months for 2 years, then every 6 months until 5 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Anne Aupérin, Cecile Le Péchoux, Estelle Rolland...
https://pubmed.ncbi.nlm.nih.gov/20351327/Arya Amini, Jinzhong Yang, Ryan Williamson...
https://pubmed.ncbi.nlm.nih.gov/22284035/Scott J Antonia, Augusto Villegas, Davey Daniel...
https://pubmed.ncbi.nlm.nih.gov/28885881/Maria Margarita Becerra Pérez, Matthew Menear, Jamie C Brehaut...
https://pubmed.ncbi.nlm.nih.gov/26975351/Huda Abusaris, Pascal R M Storchi, Rene P Brandwijk...
https://pubmed.ncbi.nlm.nih.gov/21497928/K K Ang, R E Price, L C Stephens...
https://pubmed.ncbi.nlm.nih.gov/8436524/K Bjordal, A de Graeff, P M Fayers...
https://pubmed.ncbi.nlm.nih.gov/10974628/B Bergman, N K Aaronson, S Ahmedzai...
https://pubmed.ncbi.nlm.nih.gov/8080679/K K Ang, G L Jiang, Y Feng...
https://pubmed.ncbi.nlm.nih.gov/11429229/Scott J Antonia, Augusto Villegas, Davey Daniel...
https://pubmed.ncbi.nlm.nih.gov/30280658/University of Aarhus
Lead Sponsor